These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8748631)

  • 41. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can nicotine be used medicinally in Parkinson's disease?
    Thiriez C; Villafane G; Grapin F; Fenelon G; Remy P; Cesaro P
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):429-36. PubMed ID: 22114853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do dopamine agonists provide neuroprotection?
    Yamamoto M
    Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 47. The comparative effects of medical therapies for Parkinson's disease.
    Horn S; Stern MB
    Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585
    [No Abstract]   [Full Text] [Related]  

  • 48. Initial agonist treatment of Parkinson disease: a critique.
    Albin RL; Frey KA
    Neurology; 2003 Feb; 60(3):390-4. PubMed ID: 12580185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease.
    Coletti Moja M
    Mov Disord; 2010 Jul; 25(9):1292. PubMed ID: 20310014
    [No Abstract]   [Full Text] [Related]  

  • 50. Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
    Martignoni E; Pacchetti C; Sibilla L; Bruggi P; Pedevilla M; Nappi G
    Clin Neuropharmacol; 1991 Feb; 14(1):78-83. PubMed ID: 1903079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

  • 52. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease.
    Minea D; Varga I; Falup-Pecurariu C; de Mey C; Retzow A; Althaus M
    Clin Neuropharmacol; 2001; 24(4):235-8. PubMed ID: 11479396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine agonists in Parkinson's disease.
    Tintner R; Jankovic J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1803-20. PubMed ID: 14585056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey.
    Wang V; Chao TH; Hsieh CC; Lin CC; Kao CH
    Parkinsonism Relat Disord; 2015 Jan; 21(1):18-22. PubMed ID: 25457814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms].
    Kuhn W; Müller T
    Fortschr Neurol Psychiatr; 1997 Aug; 65(8):375-85. PubMed ID: 9378450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
    Vamvakidès A
    Ann Pharm Fr; 1990; 48(2):70-80. PubMed ID: 2291602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progress in neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.